Physician profile
Lanlen Luke Venable
NPI 1306300520
$6,063.09
in general payments reported to CMS, 2019-2025
35 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,552 · 2022: $1,180 · 2023: $1,161 · 2024: $1,092 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,330.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,223.32 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $865.12 | 2021-2025 | |
| Lilly USA, LLC | $716.16 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $576.62 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $404.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $371.76 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $205.76 | 2021-2022 | |
| Amgen INC. | $183.43 | 2024-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $118.28 | 2023 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Teva Pharmaceuticals USA, INC. | $115.20 | 2021-2022 | |
| Glaxosmithkline, LLC. | $109.17 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Philips North America LLC | $103.68 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $99.46 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Exact Sciences Corporation | $94.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.70 | 2021-2025 | Xifaxan, Trulance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $77.40 | 2021 | |
| Astellas Pharma US INC | $73.42 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $66.47 | 2024-2025 | Gemtesa |
| Gilead Sciences, INC. | $63.65 | 2025 | Yeztugo |
| Sanofi-Aventis U.S. LLC | $58.77 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $58.31 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.43 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $43.12 | 2021-2023 | Unithroid |
| Ibsa Pharma INC. | $39.41 | 2022 | |
| Organogenesis INC. | $37.55 | 2022 | |
| Daiichi Sankyo INC. | $36.06 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $35.22 | 2021 | |
| Vanda Pharmaceuticals INC. | $26.35 | 2021 | |
| Boston Scientific Corporation | $26.09 | 2023 | |
| Coopersurgical, INC. | $23.35 | 2023 | Paragard T 380a |
| Xeris Pharmaceuticals, INC. | $18.98 | 2021 | |
| Seqirus USA INC | $15.88 | 2022 | |
| Dexcom, INC. | $15.25 | 2025 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $13.82 | 2022 | |
| Esperion Therapeutics, INC. | $13.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lanlen Venable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.